Proteostasis Therapeutics, Inc. (PTI) EPS Estimated At $-0.65

March 19, 2018 - By Winifred Garcia

 Proteostasis Therapeutics, Inc. (PTI) EPS Estimated At $ 0.65

Analysts expect Proteostasis Therapeutics, Inc. (NASDAQ:PTI) to report $-0.65 EPS on March, 29.They anticipate $0.27 EPS change or 71.05 % from last quarter’s $-0.38 EPS. After having $-0.56 EPS previously, Proteostasis Therapeutics, Inc.’s analysts see 16.07 % EPS growth. The stock increased 2.97% or $0.21 during the last trading session, reaching $7.29. About 4.31 million shares traded or 126.23% up from the average. Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has declined 66.87% since March 19, 2017 and is downtrending. It has underperformed by 83.57% the S&P500.

Proteostasis Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics that treat diseases caused by dysfunctional protein processing, such as cystic fibrosis. The company has market cap of $251.38 million. The Company’s lead product candidate is PTI-428, an orally bioavailable cystic fibrosis transmembrane conductance regulator modulator belonging to the amplifier class that is in Phase-I studies. It currently has negative earnings. The firm is also developing PTI-801, a corrector molecule; PTI-808, a potentiator molecule; and unfolded protein response modulators that are in preclinical development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.